How CYTALUX® is Used

Single intravenous


the recommended dose of CYTALUX as a single intravenous infusion.

Adverse reactions including nausea, vomiting, abdominal pain, flushing, hypersensitivity, elevation in blood pressure, dyspepsia, and chest discomfort were reported in patients receiving CYTALUX in clinical studies. A total of 17% of patients experienced reactions during administration of CYTALUX. Reactions typically occurred within 15 minutes of the start of infusion. CYTALUX infusion interruption or discontinuation due to adverse reactions occurred in 11% of all patients. Treatment with antihistamines and/or anti-nausea medication may be used. If an adverse reaction occurs during administration, the infusion can be interrupted and resumed after treatment of the reaction.

to surgery


CYTALUX during a 60-minute infusion, 1 to 9 hours prior to surgery for ovarian cancer and 1 to 24 hours prior to surgery for lung cancer.

Verify pregnancy status of females of reproductive potential prior to initiating CYTALUX treatment.

Illuminate with
imaging system


lesions intraoperatively using a near-infrared imaging system cleared for use with CYTALUX.

Non-fluorescing tissue in the surgical field does not rule out the presence of ovarian cancer or lesions in the lung.

Imaging system information

A near-infrared system is used to illuminate CYTALUX

Clinical data demonstrates that NIR imaging devices which excite at 760 nm to 785 nm and detect emission at 790 nm to 815 nm are suitable for use with CYTALUX.

CYTALUX is to be used with a near infrared (NIR) imaging system cleared by the FDA for specific use with pafolacianine.

CYTALUX should only be used by surgeons who have completed a training program on the use of NIR imaging systems for fluorescence imaging during surgery. Training is provided by the device manufacturer.

Get more information on Near-Infrared Imaging Systems FDA cleared for use with CYTALUX:



Speak with a representative
about CYTALUX and how to bring this technology to your OR.